Smart jab can shrink head and neck cancer tumours within six weeks, trial finds

Triple-action therapy drug amivantamab could be given as an injection to help treat recurrent or metastatic cancers

Doctors have hailed incredibly encouraging" trial results that show a triple-action smart jab can shrink tumours in head and neck cancer patients within six weeks.

Head and neck cancer is the world's sixth most common form of the disease. If it spreads or comes back after standard treatment, patients may be offered immunotherapy and platinum chemotherapy. But if this fails, there is often little else doctors can do.